Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis
Next generation product may increase gastrointestinal luminal concentration while limiting system exposure LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the first look at its late-stage RED-C clinical trial program which will be presented at the American Association for the Study of Liver Disease (AASLD), The Liver Meeting® in San Diego, CA. This clinical program was designed to assess the efficacy of a next generation therapeutic, a soluble solid dispersion (SSD) immediate-release rifaximin product, to delay onset of first overt hepatic encephalopathy (OHE) hospitalization.
Are Medical Stocks Lagging Bausch Health (BHC) This Year?
Here is how Bausch Health (BHC) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.
Why Bausch Health (BHC) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boosts Sales
BHC's third-quarter adjusted earnings and revenues beat estimates. The increase in revenue guidance is positive.
Compared to Estimates, Bausch (BHC) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Bausch (BHC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Bausch Health (BHC) Beats Q3 Earnings and Revenue Estimates
Bausch Health (BHC) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $1.03 per share a year ago.
Bausch Health Companies, Inc. (BHC) Q3 2024 Earnings Call Transcript
Bausch Health Companies, Inc. (NYSE:BHC ) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Garen Sarafian - IR Thomas Appio - CEO Jean-Jacques Charhon - EVP & CFO Conference Call Participants Mike Kovich - Cowen Les Sulewski - Truist Securities Umer Raffat - Evercore ISI David Amsellem - Piper Sandler Glen Santangelo - Jefferies Michael Freeman - Raymond James Operator Greetings. Welcome to the Bausch Health Third Quarter 2024 Earnings Call.
Bausch Health (BHC) Reports Next Week: What to Expect
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024
LAVAL, QC / ACCESSWIRE / October 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2024 financial results after market close on Wednesday, October 30, 2024. Bausch Health will host a conference call and live webcast at 5:00 p.m.
Bausch Health and Salix Survey Highlights Urgent Need for Improved Understanding of Liver Disease Across Healthcare Provider Disciplines as Prevalence of Cirrhosis Rises
Findings show care for chronic liver disease patients is falling on non-specialists who need stronger education and support to ensure patients receive timely, optimal care1 LAVAL, QC / ACCESSWIRE / October 8, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today released Liver Health Trends Report in Action, the latest Liver Health Annual Trends Report dedicated to sparking actionable change to improve liver disease management and outcomes for patients. Healthcare provider (HCP) survey participants called for holistic, multi-disciplinary treatment approaches, consistent use of non-invasive screening tools (e.g.
Bausch Health: A Buyout Bid Could Be the Ticket to Unlock Value
Bausch Health NYSE: BHC stock has been on a wild ride recently, with a dramatic surge in value over the last month. The catalyst for this surge is a wave of rumors suggesting that Bausch + Lomb NYSE: BLCO, Bausch Health's spinoff eye care business, is considering a buyout.
Here's Why Bausch Health Stock Gained 14.7% in a Week
BHC stock rises 14.7% in a week after a report surfaced that the company is in talks with Jefferies Financial Group to push out maturities on some of its debt.
